SEARCH

SEARCH BY CITATION

References

  • 1
    Ducy P, Schinke T, Karsenty G 2000 The osteoblast: A sophisticated fibroblast under central surveillance. Science 289:15011504.
  • 2
    Teitelbaum SL 2000 Bone resorption by osteoclasts. Science 289:15041508.
  • 3
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315323.
  • 4
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Oian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldy G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165176.
  • 5
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:35973602.
  • 6
    Akatsu T, Murakami T, Nishakawa N, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motovoshi K, Nagata N 1998 Osteoclastogenesis-inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclasts. Biochem Biophys Res Commun 250:229234.
  • 7
    Boyle WJ, Scott SW, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337342.
  • 8
    Takayanagi H 2005 Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83:170179.
  • 9
    Bharti AC, Takada Y, Shishodia S, Aggarwal BB 2004 Evidence that receptor activator of nuclear factor (NF)-kB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kB-independent and TRAF6-dependent mechanism. J Biol Chem 7:60656076.
  • 10
    Wu X, Pan G, McKenna MA, Zayzafoon M, Xiong W-C, McDonald JM 2005 RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts. J Bone Miner Res 20:107116.
  • 11
    Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T 2002 Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889901.
  • 12
    Komarova SV, Pilkington MF, Weidema F, Dixon SJ, Sims SM 2003 RANK ligand-induced elevation of cytosolic Ca2+ accelerates nuclear translocation of nuclear factor kB in osteoclasts. J Biol Chem 278:82868293.
  • 13
    Hirotani H, Tuohy NA, Woo J-T, Stern PH, Clipstone NA 2004 The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem 279:1398413992.
  • 14
    Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, Choi Y 1999 TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 4:10411049.
  • 15
    Arron JR, Vologodskaia M, Wong BR, Naramura M, Kim N, Gu H, Choi Y 2001 A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (TRANCE) and CD40L-mediated Akt activation. J Biol Chem 26:3001130017.
  • 16
    Chen J, Shapiro HS, Sodek J 1992 Developmental expression of bone sialoprotein mRNA in rat mineralized connective tissues. J Bone Miner Res 8:987997.
  • 17
    Ganss B, Kim RH, Sodek J 1999 Bone sialoprotein. Crit Rev Oral Biol Med 10:7998.
  • 18
    Tye CE, Rattray KR, Warner KJ, Gordon JA, Sodek J, Hunter GK, Goldberg HA 2003 Delineation of the hydroxyapatite-nucleating domains of bone sialoprotein. J Biol Chem 278:79497955.
  • 19
    Helfrich MH, Nesbitt SA, Dorey EL, Horton MA 1992 Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via αvβ3 integrin. J Bone Miner Res 7:335342.
  • 20
    Flores ME, Norgard M, Heinegard D, Reinholt FP, Andersson G 1992 RGD-directed attachment of isolated rat osteoclasts to osteopontin, bone sialoprotein, and fibronectin. Exp Cell Res 201:526530.
  • 21
    Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, Mintz KA, Robey PG, Teitelbaum SL, Sheresh DA 1993 Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin αvβ3 potentiate bone resorption. J Biol Chem 13:99019907.
  • 22
    Raynal C, Delmas PD, Chenu C 1995 Bone sialoprotein stimulates in vitro bone resorption. Endocrinology 137:23472354.
  • 23
    Sanjai A, Houghton A, Neff L, DiDomenico E, Bardelay C, Antoine E, Levy J, Gilit J, Bowtell D, Horne WC, Baron R 2001 Cbl associates with Pyk2 and Src to regulate Src kinase activity, αvβ3 integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 152:181195.
  • 24
    Miyazaki T, Sanjai A, Neff L, Tanaka S, Horne WC, Baron R 2004 Src kinase activity is essential for osteoclast function. J Biol Chem 279:1766017666.
  • 25
    Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG, Teitelbaum SL 1997 A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 99:22842292.
  • 26
    McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL 2000 Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:433440.
  • 27
    Soriano P, Montgomery C, Geske R, Bradley A 1991 Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693702.
  • 28
    Shankar G, Gadek TR, Burdick DJ, Davidson I, Mason WT, Horton MA 1995 Structural determinants of calcium signaling by RGD peptides in rat osteoclasts: Integrin-dependent and -independent actions. Exp Cell Res 219:364371.
  • 29
    Shaarawy M, Hasan M 2001 Serum bone sialoprotein: A marker of bone resorption in postmenopausal osteoporosis. Scand J Clin Lab Invest 61:513522.
  • 30
    Jung K, Lein M, Stephan C, Hosslin KV, Semjonow A, Sinha P, Loening SA, Schnorr D 2004 Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer 111:783791.
  • 31
    Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW 2001 Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:40604066.
  • 32
    Hofbauer LC, Heufelder AE 2001 Role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243253.
  • 33
    Wu X, McKenna MA, Feng X, Nagi TR, McDonald JM 2003 Osteoclast apoptosis: The role of Fas in vivo and in vitro. Endocrinology 144:55455555.
  • 34
    Tu Q, Yamauchi M, Pageau SC, Chen JJ 2004 Autoregulation of bone sialoprotein gene in pre-osteoblastic and non-osteoblastic cells. Biochem Biophys Res Commun 316:461467.
  • 35
    Valverde P, Koren G 1999 Purification and preliminary characterization of a cardiac Kv1.5 repressor element-binding factor. Circ Res 84:937944.
  • 36
    Valverde P, Obin M, Taylor A 2004 Role of Axl/Gas6 signaling in lens epithelial cell proliferation and survival. Exp Eye Res 78:2737.
  • 37
    Danial NN, Korsmeyer SJ 2004 Cell death: Critical control points. Cell 116:205219.
  • 38
    Chan TO, Rittenhouse SE, Tsichlis PN 1999 AKT/PKB and other D3 phosphoinositide-regulated kinases:kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 68:9651014.
  • 39
    Lee SE, Chung WJ, Kwak HB, Chung CH, Kwack KB, Lee ZH, Zim HH 2001 Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of AKT and ERK. J Biol Chem 276:4934349349.
  • 40
    Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T 2004 Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428:758763.
  • 41
    Mocsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, Spusta SC, Majumdar S, Lanier LL, Lowel CA, Nakamura MC 2004 The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 101:61586163.
  • 42
    Faccio R, Zou W, Colaianni G, Teitelbaum SL, Ross FP 2003 High dose M-CSF partially rescues the Dap12−/− osteoclast phenotype. J Cell Biochem 90:871883.
  • 43
    Feng X 2005 Regulatory roles and molecular signaling of the TNF family members in osteoclasts. Gene 350:113.
  • 44
    Gingery A, Bradley E, Shaw A, Oursler MJ 2003 Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem 89:165179.
  • 45
    Sugatani T, Hruska KA 2005 Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable of cell survival in isolated osteoclast precursors. J Biol Chem 280:35833589.
  • 46
    Igarashi K, Hirotani H, Woo JT, Stern PH 2004 Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures. Bone 35:4756.
  • 47
    Stupack DG, Puente XS, Boutsaboualoy S, Stargard CM, Cheresh DA 2001 Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 155:459470.
  • 48
    Zhao H, Ross FP, Teitelbaum SL 2004 Unoccupied αvβ3 integrin regulates osteoclast apoptosis by transmitting a positive death signal. Mol Endocrinol 19:771780.